Prelude Therapeutics

Prelude Therapeutics is a clinical-stage precision oncology company focused on creating drug candidates by targeting specific pathways in cancer cells. The company uses Prelude Drug Discovery Engine to design, synthesize, and test targets. Furthermore, the company claims its pipeline, which targets CDK9, MCL-1, CDK4/6, and SMARCA2, is highly differentiated in terms of modalities and properties. 

As of June 2024, the company’s pipeline included three candidates in Phase I clinical trials: 1) PRT7732, a potent, orally administered degrader of SMARCA2 that demonstrates >3000-fold selectivity for SMARCA2 relative to SMARCA4 in cell-based assays, 2) PRT3789, the first protein degrader of SMARCA2/BRM in its class to treat genomically selected cancers, and 3) PRT2527, a potent and highly selective CDK9 inhibitor targeting patients whose cancers are likely to be dependent on CDK9. It also had two other therapeutics programs in the discovery stage. 

Key Customers and Partnerships

In March 2023, the company partnered with global biotechnology company BeiGene to investigate the efficacy of its experimental CDK9 inhibitor, PRT2527.